Carcinoma of the Head and Neck Clinical Trial
Official title:
Phase II Trial of Taxotere and Oxaliplatin Combination Chemotherapy in Squamous Cell Carcinoma of the Head and Neck
This research study is for subjects with squamous cell cancer of the head and neck which is
not solely treatable with surgery or radiation. This research study involves treatment with
an experimental chemotherapy combination of oxaliplatin and Taxotere. Tha main purpose of
this study is to assess the effectiveness of this combination of medications for this type
of cancer.
Approximately 54 subjects will take part in this study.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00257335 -
Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT00865098 -
Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
|
Phase 2 | |
| Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
| Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
| Completed |
NCT03733210 -
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
|
Phase 1 | |
| Recruiting |
NCT03001570 -
Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District
|
Phase 2 | |
| Completed |
NCT02626000 -
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
|
Phase 1 | |
| Completed |
NCT00050388 -
Phase II Trial of Allovectin-7® for Head and Neck Cancer
|
Phase 3 |